Abstract
To search for potential mechanism that might alter synaptic transmission following Aβ increase we have examined the presynaptic component of transmitter release. As parameters of synaptic transmission that might underlie presynaptic mechanisms, we have used paired-pulse facilitation (PPF), post-tetanic potentiation (PTP), and synaptic fatigue (SF) at the connection between the hippocampal Schaffer-collateral pathway and CA1 pyramidal neurons in ∼5 month old double transgenic mice overexpressing the mutated form of amyloid precursor protein (APPK670N, M671L) and presenilin 1 (PS1M146V). While the presynaptic mechanisms of PPF and PTP were not compromised in the APP / PS1 mice, SF was more pronounced in the double transgenic animals. The percentage of the 40th fEPSP slope over the first during the tetanus was 18 ± 3% in APP / PS1 vs. 26 ± 2% in WT. Thus, it is likely that presynaptic mechanisms underlying SF but not PPF and PTP, may account for synaptic dysfunction in APP / PS1 mice.
Keywords: synapse, amyloid, synaptic fatigue, post-tetanic potentiation, paired pulse facilitation, neurotransmitter release, alzheimers disease
Current Alzheimer Research
Title: Synaptic Fatigue is More Pronounced in the APP/PS1 Transgenic Mouse Model of Alzheimers Disease
Volume: 2 Issue: 2
Author(s): Hong Zhang, Bing Gong, Shumin Liu, Mauro Fa, Ipe Ninan, Agnieszka Staniszewski and Ottavio Arancio
Affiliation:
Keywords: synapse, amyloid, synaptic fatigue, post-tetanic potentiation, paired pulse facilitation, neurotransmitter release, alzheimers disease
Abstract: To search for potential mechanism that might alter synaptic transmission following Aβ increase we have examined the presynaptic component of transmitter release. As parameters of synaptic transmission that might underlie presynaptic mechanisms, we have used paired-pulse facilitation (PPF), post-tetanic potentiation (PTP), and synaptic fatigue (SF) at the connection between the hippocampal Schaffer-collateral pathway and CA1 pyramidal neurons in ∼5 month old double transgenic mice overexpressing the mutated form of amyloid precursor protein (APPK670N, M671L) and presenilin 1 (PS1M146V). While the presynaptic mechanisms of PPF and PTP were not compromised in the APP / PS1 mice, SF was more pronounced in the double transgenic animals. The percentage of the 40th fEPSP slope over the first during the tetanus was 18 ± 3% in APP / PS1 vs. 26 ± 2% in WT. Thus, it is likely that presynaptic mechanisms underlying SF but not PPF and PTP, may account for synaptic dysfunction in APP / PS1 mice.
Export Options
About this article
Cite this article as:
Zhang Hong, Gong Bing, Liu Shumin, Fa Mauro, Ninan Ipe, Staniszewski Agnieszka and Arancio Ottavio, Synaptic Fatigue is More Pronounced in the APP/PS1 Transgenic Mouse Model of Alzheimers Disease, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585936
DOI https://dx.doi.org/10.2174/1567205053585936 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Disease-Modifying Therapies in Frontotemporal Lobar Degeneration
Current Medicinal Chemistry Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy
Infectious Disorders - Drug Targets Gene-Gene and Gene-Environment Interaction on the Risk of Parkinson’s Disease
Current Aging Science Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience
Current Alzheimer Research Autophagy in the Central Nervous System: Implications for Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Receptor-Interacting Protein Kinase 1 (RIPK1) as a Potential Therapeutic Target: An Overview of Its Possible Role in the Pathogenesis of Alzheimer's Disease
Current Alzheimer Research The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Current Pharmaceutical Design Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Current Alzheimer Research Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design Editorial:Genomics and Epigenomics of Tumor and Aging Cells
Current Genomics Pharmacomimetics of Exercise: Novel Approaches for Hippocampally- Targeted Neuroprotective Agents
Current Medicinal Chemistry Present Status of Management of Mentally Ill Offenders in Japan: Critical Perspective from a Viewpoint of General Psychiatrist
Current Psychiatry Reviews Peptides for Therapy and Diagnosis of Alzheimer's Disease
Current Pharmaceutical Design A comparative <i>in vivo</i> Evaluation of Anti-Alzheimer Activity of Bacopa Extract and its Solid Lipid Nanoparticles
Current Bioactive Compounds An Automatic Telemonitoring System for Elderly People at Home
International Journal of Sensors, Wireless Communications and Control Heart Rate Variability Indexes in Dementia: A Systematic Review with a Quantitative Analysis
Current Alzheimer Research An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Issues of Quantitative Metabolic Brain Imaging with Small Animal PET in Mice
Current Medical Imaging The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain
Current Neuropharmacology